NewsLocal News

Actions

Kansas to get $27.6M from firm investigated over drug costs

Posted at 3:37 PM, Dec 06, 2021
and last updated 2021-12-06 16:37:58-05

Kansas will receive nearly $27.6 million from a legal settlement with the company that manages prescription costs for its Medicaid program, after an investigation into whether the company had overcharged the state, Attorney General Derek Schmidt announced Monday.

The settlement with St. Louis-based Centene Corp. comes after a nearly two-year investigation by Schmidt's office and a Jackson, Mississippi-area law firm it hired to review Centene's practices. States throughout the country have been investigating companies known as pharmacy benefit managers, and Mississippi and Ohio in June settled lawsuits against Centene for a total of nearly $144 million.

Kansas settled with Centene before filing its lawsuit. Schmidt said a key concern was whether Centene negotiated discounts with drug companies and failed to notify Kansas or pass along the savings.

"Kansas was not in a position to detect that through ordinary financial reviews because the company wasn't providing sufficiently detailed data," Schmidt told The Associated Press.

The state's $4 billion a year Medicaid program provides health coverage to 419,000 low-income, disabled or elderly residents. Schmidt said the settlement also will require Centene to provide more detailed data to the program going forward.

The company denied any wrongdoing as part of the settlement. It didn't immediately respond to an email sent Monday seeking comment about the deal.

Prescriptions cost the Kansas Medicaid program more than $100 million per year after rebates from drug companies, according to the Kaiser Family Foundation. Schmidt's investigation covered Centene's actions since the start of 2016.

Schmidt said the review began in 2019 after Ohio's attorney general identified potential issues in that state. The law firm Schmidt's office hired, Liston & Deas, also worked for Ohio and Mississippi.

"We're taking a hard look at whether there is similar behavior by other companies in other parts of state government," Schmidt said, declining to provide details about other investigations.